Live
Clinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune DiseaseCellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsAmgenAmgen: A Biotech Giant's Path to Recovery and Growth - AOL.comAmgenAmgen: A Biotech Giant's Path to Recovery and Growth - The Motley Fool
10x Genomics Blog 2. Dez. 2025

Morgan Stanley Downgrades 10x Genomics to Equalweight From Overweight, Lifts Price Target to $20 From $17 - MarketScreener

Morgan Stanley Downgrades 10x Genomics to Equalweight From Overweight, Lifts Price Target to $20 From $17 - MarketScreener

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.